BeiGene, a Beijing-based bio/pharmaceutical company specializing in oncology, has opened a $800-million biomanufacturing facility and clinical research and development center in Hopewell, New Jersey. 

BeiGene’s $800-million investment is the culmination of a three-year project to expand the company’s manufacturing and research and development footprint in the US. The company says it plans to create hundreds of jobs at the site by the end of 2025.  

BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines currently and in the future. The company develops in-house programs as well as partners with other bio/pharmaceutical companies, which includes Amgen, Pfizer, Bristol-Myers Squibb (through it acquisition of Mirati Therapeutics), and Zymeworks, among others. It has over 10,000 employees worldwide, primarily in the US, China, and Europe.

The site features approximately 400,000 square feet of dedicated commercial-stage biomanufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The facility adds to BeiGene’s late-stage research and clinical development capabilities.  

Source: BeiGene